Frost Radar™: Laboratory Automation Systems, 2025

Healthcare Frost Radar™: Laboratory Automation Systems, 2025

A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines

INDUSTRY
Healthcare

RELEASE DATE
09-Oct-2025
REGION
Global
DELIVERABLE TYPE
Frost Radar

RESEARCH CODE
PG2P-01-00-00-00
SKU
HC_2025_34100
Yes
SHARE
$4,950.00
In stock
SKU
HC_2025_34100

Frost Radar™: Laboratory Automation Systems, 2025
Published on: 09-Oct-2025 | SKU: HC_2025_34100

Need more details?
$4,950.00
Need more details?

The pathology workforce shortage, accuracy concerns, and uneven distribution of prices and resources remain persistent challenges for the diagnostics sector. Automation, a broad concept encompassing processes and practices that streamline workflows, save time, and manage increasing workloads, has become a key response to these issues. By combining hardware and software systems, laboratory automation delivers multiple solutions that reduce costs, minimize human error, and enhance the reliability of clinical workflows, the development of medicines and vaccines, and the efficiency of research processes.

The market is being shaped by the growing adoption of automation systems, alongside increased demand for specialized testing and the influence of new sciences, such as CRISPR, large molecule development, and CAR-T therapy. While the automated liquid handling and sample management system markets are well-established and competitive, the workflow automation system market shows strong growth potential, driven in part by small and midsized vendors offering cloud-based orchestration for workflow management, simulation, and execution. This Frost Radar™ benchmarked companies and their automated liquid handling, sample management, and workflow automation solutions. Companies were selected based on revenue share and the strength of their portfolio across at least two of these market segments. Revenue share is categorized as high (10% or more), medium (2%–9%), or low (less than 2% or absence of a strong product portfolio). The analysis highlights 13 companies that generated revenue from these solutions between 2021 and 2024.

Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar™. The publication presents competitive profiles of each company on the Frost Radar™ considering their strengths and the opportunities that best fit those strengths.

Abbott

Agilent Technologies

Azenta Life Sciences

BD

Beckman Coulter

Bio-Rad Laboratories

Eppendorf

Hamilton Company

Revvity

Roche Diagnostics

Siemens Healthineers

Tecan

Thermo Fisher Scientific

Significance of Being on the Frost Radar

CEO’s Growth Team

Investors

Customers

Board of Directors

Frost Radar™: Benchmarking Future Growth Potential 2 Major Indices, 10 Analytical Ingredients, 1 Platform

Growth Index

Growth Index (GI) is a measure of a company’s growth performance and track record, along with its ability to develop and execute a fully aligned growth strategy and vision; a robust growth pipeline system; and effective market, competitor, and end-user focused sales and marketing strategies.

  • Market Share (previous 3 years)
    This is a comparison of a company’s market share relative to its competitors in a given market space for the previous 3 years.
  • Revenue Growth (previous 3 years)
    This is a look at a company’s revenue growth rate for the previous 3 years in the market/industry/category that forms the context for the given Frost Radar™.
  • Growth Pipeline
    This is an evaluation of the strength and leverage of a company’s growth pipeline system to continuously capture, analyze, and prioritize its universe of growth opportunities.
  • Vision and Strategy
    This is an assessment of how well a company’s growth strategy is aligned with its vision. Are the investments that a company is making in new products and markets consistent with the stated vision?
  • Sales and Marketing
    This is a measure of the effectiveness of a company’s sales and marketing efforts in helping it drive demand and achieve its growth objectives.

Innovation Index

Innovation Index (II) is a measure of a company’s ability to develop products/ services/ solutions (with a clear understanding of disruptive Mega Trends) that are globally applicable, are able to evolve and expand to serve multiple markets and are aligned to customers’ changing needs.

  • INNOVATION SCALABILITY
    This determines whether an organization’s innovations are globally scalable and applicable in both developing and mature markets, and also in adjacent and non-adjacent industry verticals.
  • RESEARCH AND DEVELOPMENT
    This is a measure of the efficacy of a company’s R&D strategy, as determined by the size of its R&D investment and how it feeds the innovation pipeline.
  • PRODUCT PORTFOLIO
    This is a measure of a company’s product portfolio, focusing on the relative contribution of new products to its annual revenue.
  • MEGATRENDS LEVERAGE
    This is an assessment of a company’s proactive leverage of evolving, long-term opportunities and new business models, as the foundation of its innovation pipeline.
  • CUSTOMER ALIGNMENT
    This evaluates the applicability of a company’s products/services/solutions to current and potential customers, as well as how its innovation strategy is influenced by evolving customer needs.

Significance of Being on the Frost Radar™

Companies plotted on the Frost RadarTM are the leaders in the industry for growth, innovation, or both. They are instrumental in advancing the industry into the future.

  • GROWTH POTENTIAL
    Your organization has significant future growth potential, which makes it a Company to Action.
  • BEST PRACTICES
    Your organization is well positioned to shape Growth Pipeline™ best practices in your industry.
  • COMPETITIVE INTENSITY
    Your organization is one of the key drivers of competitive intensity in the growth environment.
  • CUSTOMER VALUE
    Your organization has demonstrated the ability to significantly enhance its customer value proposition.
  • PARTNER POTENTIAL
    Your organization is top of mind for customers, investors, value chain partners, and future talent as a significant value provider.

Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related In Vitro Diagnostics (IVD) research

27 Aug 2026   |   Global   |   Frost Radar

Frost Radar: AI-Powered Molecular Diagnostics, 2026

AI-powered molecular diagnostics is an emerging and moderately fragmented industry that includes molecular diagnostics companies, precision medicine platforms, sequencing specialists, AI-driven analytics providers, and disease-focused biotechnology companies. No single company has dominated, present...

25 Aug 2026   |   Global   |   Technology Research

Breakthrough Innovations in Point-of-Care Diagnostics

This research analyzes how point-of-care (PoC) diagnostics is evolving from simple tests to decentralized, connected, and clinically actionable testing platforms across hospitals, outpatient settings, homes, and pharmacies.

The study assesses key technology shifts, including rapid molecular t...

21 Aug 2026   |   Global   |   Technology Research

Innovations and Growth Opportunities in AI-Driven Biomanufacturing, Advanced Cell and Gene Therapies, and Precision Immunotherapy

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping biomanufacturing, cell and gene therapy, precision immunotherapy, anti-infectives, and neurotherapeutics across oncology, infectious disease...

07 Aug 2026   |   Global   |   Customer Research

Laboratory Product Purchasing Trends, United States and Europe, 2025–2026

Qualified respondents to this Frost & Sullivan survey were invited to participate in an online survey examining their laboratory’s product purchasing process in 2025 and expectations for 2026. Frost & Sullivan has conducted similar studies among the same target respondent groups since 2012. The su...

21 Jul 2026   |   Global   |   Market Research

Point-of-Care Testing Market, Global, 2024–2031

The global POCT market is rapidly evolving from standalone rapid diagnostics to connected, AI-enabled clinical intelligence ecosystems that support decentralized healthcare delivery. Growth is driven by the increasing demand for faster clinical decision-making, early disease detection, personalized ...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

The pathology workforce shortage, accuracy concerns, and uneven distribution of prices and resources remain persistent challenges for the diagnostics sector. Automation, a broad concept encompassing processes and practices that streamline workflows, save time, and manage increasing workloads, has become a key response to these issues. By combining hardware and software systems, laboratory automation delivers multiple solutions that reduce costs, minimize human error, and enhance the reliability of clinical workflows, the development of medicines and vaccines, and the efficiency of research processes.

The market is being shaped by the growing adoption of automation systems, alongside increased demand for specialized testing and the influence of new sciences, such as CRISPR, large molecule development, and CAR-T therapy. While the automated liquid handling and sample management system markets are well-established and competitive, the workflow automation system market shows strong growth potential, driven in part by small and midsized vendors offering cloud-based orchestration for workflow management, simulation, and execution. This Frost Radar™ benchmarked companies and their automated liquid handling, sample management, and workflow automation solutions. Companies were selected based on revenue share and the strength of their portfolio across at least two of these market segments. Revenue share is categorized as high (10% or more), medium (2%–9%), or low (less than 2% or absence of a strong product portfolio). The analysis highlights 13 companies that generated revenue from these solutions between 2021 and 2024.

Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar™. The publication presents competitive profiles of each company on the Frost Radar™ considering their strengths and the opportunities that best fit those strengths.
More Information
Deliverable Type Frost Radar
Industries Healthcare
No Index No
Is Prebook No
Podcast No
Predecessor None
WIP Number PG2P-01-00-00-00